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Abstract Rationale: Delta-opioid agonists produce a
number of behavioral effects, including convulsions, anti-
nociception, locomotor stimulation, and antidepressant-
like effects. The development of these compounds as
treatments for depression is limited by their convulsive
effects. Therefore, determining how to separate the con-
vulsive and antidepressant-like characteristics of these
compounds is essential for their potential clinical use.
Objective: The present study tests the hypothesis that the
rate of delta-opioid agonist administration greatly con-
tributes to the convulsive properties, but not the anti-
depressant-like effects, of delta-opioid agonists. Materials
and methods: The delta-opioid agonist SNC80 (1, 3.2, and
10 mg kg−1 or vehicle) was administered to Sprague–
Dawley rats by intravenous infusion over different dura-
tions of time (20 s, 20, or 60 min). Convulsions were
measured by observation prior to determining antidepres-
sant-like effects in the forced swim test. Results: Slowing
the rate of SNC80 administration minimized delta ago-
nist-induced convulsions without altering the effects of
SNC80 in the forced swim test. Conclusions: These data
suggest that delta agonist-induced antidepressant prop-
erties are independent of convulsive effects, and that it
may be possible to eliminate the convulsions produced
by delta agonists, further promoting their potential clinical
utility.
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Introduction
Previous studies have shown that disregulation of the delta-
opioid receptor system may be related to depression or
depressive symptoms and, therefore, may be a useful thera-
peutic target for treating depression. It was demonstrated
that mice lacking the delta-opioid receptor displayed altered
emotional responses that are consistent with a depressive-
like profile of behaviors (Filliol et al. 2000). In addition,
compounds that activated the delta-opioid receptor have
been shown to have antidepressant-like properties in a
number of animal models. The selective delta-opioid ago-
nist Tyr-D-Ser-(O–C(CH3)3)-Gly-Phe-Leu-Thr-(O–C(CH3)3
(BUBU) produced antidepressant-like effects in the learned
helplessness model of depression (Tejedor-Real et al.
1998). Similarly, increasing levels of endogenous delta-
opioid peptides with enkephalinase inhibitors such as
RB101 revealed antidepressant-like effects in models of
depression in mice and rats (Baamonde et al. 1992;
Tejedor-Real et al. 1998). More recently, the nonpeptidic
delta-opioid agonists SNC80 and (+)BW373U86 dis-
played naltrindole (NTI)-sensitive antidepressant-like prop-
erties in the forced swim test in rats (e.g., Broom et al.
2002a; Jutkiewicz et al. 2004). Overall, these findings
suggest that activation of delta-opioid receptors may have
therapeutic potential to treat depression.
In addition to antidepressant-like effects, delta-opioid re-
ceptor agonists produce convulsions, antinociception, and
locomotor stimulation. Delta-opioid agonist-induced con-
vulsions have been observed in mice, rats, and monkeys
(Broom et al. 2002a; Comer et al. 1993; Dykstra et al. 1993;
Hong et al. 1998; Negus et al. 1994; Pakarinen et al. 1995). It
has been suggested that delta-opioid agonists may produce
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antidepressant-like effects through a mechanism similar to
electroconvulsive shock (Comer et al. 1993). However,
Broom et al. (2002b) demonstrated that preventing convul-
sions with the anticonvulsant benzodiazepine, midazolam,
did not alter the antidepressant-like properties of the delta-
opioid agonist (+)BW373U86, suggesting that the antide-
pressant-like effects did not require a convulsive event. Thus,
minimizing the undesirable convulsive effects while retain-
ing the antidepressant-like properties appears feasible. In
particular, the latency to convulsion shortens with increasing
the dose of agonist (Broom et al. 2002a) and with different
routes of administration (Jutkiewicz et al. 2004), indicating
that the speed with which drug enters the circulation and/or
the central nervous system (CNS) may play a role in delta-
opioid-mediated convulsions. These preliminary data sug-
gested that it might be possible to alter the time to onset
of convulsion and, possibly, other characteristics of this
behavior.
Previous studies have reported that varying the rate of
administration alters the effects of different CNS drugs. For
example, it was demonstrated that pharmacokinetic vari-
ables are an important determinant of the functional re-
sponse of cocaine as measured by route-dependent neuronal
circuit activation (Porrino 1993). Varying the rate of
intravenous drug administration also altered the subjective
effects of cocaine, but not some of the physiological effects
of cocaine (Abreu et al. 2001). Similarly, the rate of
intravenous cocaine administration changed the suscepti-
bility to cocaine-induced locomotor sensitization in rats
(Samaha et al. 2002). Likewise, oral administration of
immediate-release methylphenidate produced subjective
andcardiovascular effects,while the sustained-releasemeth-
ylphenidate formulation only produced changes in cardio-
vascular function (Kollins et al. 1998). In another drug
class, rapid-onset diazepam produced more euphoria, ob-
servable signs of intoxication, psychomotor impairment,
and longer-lasting sedation as compared with slow-onset
diazepam (de Wit et al. 1993). In general, these studies
demonstrate that rate of administration can alter the phys-
iological, behavioral, and subjective effects of various
classes of drugs.
The experiments, described herein, manipulated the rate
at which the delta-opioid agonist SNC80 was administered
intravenously to investigate how rate of administration
changes its convulsive and antidepressant-like properties.
It was hypothesized that reducing the rate of SNC80 ad-
ministration would minimize the convulsive effects while
preserving the antidepressant-like properties of the delta-
opioid agonist. Multiple factors might contribute to the
potential differences between these behavioral effects, in-
cluding the quantity and the rate of drug accessing the site
of action, tolerance development, and the time at which the
behavioral effects are measured. The quantity of SNC80




Male Sprague–Dawley rats (250–350 g) were obtained
from Harlan Sprague Dawley (Indianapolis, IN) and were
housed in groups of three to four rats per cage prior to
surgery. The rats were implanted with intravenous catheters
3–7 days after arrival and were then housed singly until
termination of the study. All animals were fed a standard
laboratory diet, and the housing room was maintained on a
12-h light/dark cycle, with lights on at 7:00 A.M. Studies
were performed in accordance with the Declaration of
Helsinki and with the Guide for the Care and Use of Lab-
oratory Animals, as adopted and promulgated by the
National Institutes of Health, and were approved by the
University of Michigan University Committee on the Use
and Care of Animals.
Procedures
Surgical procedures
Catheters were constructed from approximately 15 cm
of Micro-Renathane tubing (MRE-040, Braintree Scien-
tific, Inc, Braintree, MA). Intravenous catheters were
implanted as described previously (Baird et al. 2000).
Briefly, rats were anesthetized with ketamine hydro-
chloride (100 mg kg−1, i.p.) and xylazine hydrochloride
(10 mg kg−1, i.p.). The right jugular vein was isolated, and
approximately 3 cm of the catheter was inserted into it and
secured to the surrounding tissues. The remaining tubing
was threaded subcutaneously to a dorsal incision point and
secured to the musculature directly below the incision. The
2–3 cm of tubing that remained exposed outside the rat’s
body was plugged with a stainless steel pin (McMaster–
Carr, Chicago, IL). Immediately after, and every day
following the surgery, the catheters were flushed with
approximately 0.5 ml of heparinized saline (50 U ml−1).
On average, rats were allowed 4–5 days of recovery from
surgery before being used in an experiment.
Intravenous drug infusions
Rats were administered vehicle or drug solutions either s.c.
or i.v. Intravenous infusions of either 1, 3.2, or 10 mg kg−1
SNC80 or vehicle were administered over one of three
infusion durations: 20 s, 20, or 60 min. For the 20-s in-
fusion, the catheter was simply attached to a syringe, and
the experimenter infused a single dose over 20 s. For the
20- and 60-min infusion rates, the catheter was attached to
a syringe on an infusion pump (Harvard Apparatus, Natick,
MA), and the pump administered a single dose (1, 3.2, or
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10 mg kg−1 or vehicle) at a constant speed over 20 or
60 min. During pump-operated drug infusions, the catheter
was attached to a swivel, which allowed the rat to move
freely around the cage. For antagonism studies, NTI (0.1, 1,
or 10 mg kg−1) was administered s.c. 30 min prior to the
start of an infusion of SNC80.
Convulsion observation
The observation of convulsant activity was performed as
previously described for rats (Broom et al. 2002a). Briefly,
rats were placed individually in plastic observation cages
with bedding and observed for 20 min after the s.c. in-
jection or during the i.v. infusion and for 20 min following
the termination of the i.v. infusion. In general, convulsant
activity occurred as clonic movements of the head, face,
and forepaws. Postconvulsion catalepsy was identified as
failing to remove its paws from a horizontal rod within 15 s
and by the loss of the righting reflex. The qualitative nature
of the convulsive events (in terms of intensity) was deter-
mined by behavioral observation and recorded by observ-
ers blind to treatment.
Convulsion threshold determination
The method used to determine the threshold dose re-
quired for a convulsion in rats was derived from studies
measuring the threshold dose of pentylenetetrazol (Pollack
and Shen 1985). For these experiments, rats with im-
planted i.v. catheters (described above) were injected s.c.
with vehicle or one dose of SNC80 1 h prior to receiving
an i.v. infusion of 0.5 mg kg−1 min−1 SNC80 (10 mg kg−1
SNC80 over 20 min). The infusion was terminated at the
first sign of repeated clonic muscle contractions of the
head or forelimbs. The amount of drug infused was re-
corded and used to calculate the convulsive threshold dose
(i.e., the dose of drug that produced a convulsion). Based
on these studies, a shift in the convulsive threshold dose
following different SNC80 pretreatments can be deter-
mined. For example, if SNC80 pretreatment induces tol-
erance, then a larger threshold dose would be required to
produce a convulsion. Infusions were limited to 1 h (to
conserve compound), such that the total dose received did
not exceed 30 mg kg−1.
Forced swim test
Rats were evaluated in the 1-day forced swim test as
previously described (Broom et al. 2002a,b) 30 min
following the termination of any i.v. drug infusion or
60 min after an s.c. injection following convulsion ob-
servation. Briefly, male Sprague–Dawley rats were placed
in a clear acrylic, cylindrical container (46-cm tall×20-cm
diameter) filled with 30 cm of 25°C (±1°C) water. The
15-min swim session was videotaped from above the
tank for later scoring. Swim tank water was changed after
every rat. Following the swim session, rats without i.v.
catheters were removed from the water, towel-dried,
placed in a heated cage for 15 min, and sacrificed by
100 mg kg−1 s.c. administration of pentobarbital. After
swimming, rats with i.v. catheters were killed by i.v.
administration of pentobarbital (100 mg kg−1) to insure
catheter patency; only data from rats with patent catheters
were used.
An observer, blind to the drug treatment conditions,
analyzed the videotaped swim session and scored one
behavioral measure every 5 s for the 15-min swim session.
Every 5 s, the behavior was scored as immobility, swim-
ming, or climbing (Detke et al. 1995). Immobility was
described as floating in the water using only small move-
ments to keep the head above water. Swimmingwas defined
as traveling around the swim tank while actively moving
paws and keeping paws below the water surface. Climbing
was described as actively moving the paws into and out of
the water.
Ex vivo [3H]NTI-binding experiments
Rats (N=3 per condition) were administered vehicle, 1.0,
3.2, or 10 mg kg−1 SNC80 over a 20-s, 20-, or 60-min
i.v. infusion duration. Rats were sacrificed by decapitation
30 min after the infusion ended (at the time rats would
normally be evaluated in the forced swim test); the cer-
ebellum was removed, and the brains were submerged
in 10 ml of ice-cold 50 mM Tris (pH 7.4). The brains
were homogenized, divided into 1-ml aliquots, and flash-
frozen. Competition-binding experiments were conducted
in a 2-ml volume assay. For standard curve determi-
nations, 400 μl of vehicle-treated rat brains were added
to 20 μl of a known concentration of SNC80 (0.032–
10 μM) and 20 μl of 0.1 nM [3H]NTI. Known con-
centrations of SNC80 diluted in 0.1% bovine serum
albumin (BSA) were added to the assay tubes with Sig-
macote-coated (Sigma, St. Louis, MO) pipette tips. All
brain samples from drug-treated rats were evaluated
simultaneously with the standard curves. To calculate
brain concentrations of drug, 400 μl of treated rat brains
were added to 20 μl of 0.1% BSA and 20 μl of 0.1 nM
[3H]NTI. To attain the final assay volume, 1.56 ml
50 mM Tris (pH 7.4) was added to all tubes. All samples
were vortexed and incubated in a 25°C water bath for
60 min. Following incubation, the samples were quickly
filtered through glass fiber filters (Schleicher and Schuell
no.32, Keene, NH) and soaked in 0.1% polyethylenimine
(Sigma) that were mounted in a Brandel cell harvester
(Biomedical Research and Development Laboratories,
Gaithersburg, MD). Each filter was removed and placed
in a 5-ml polypropylene scintillation vial with 4 ml
scintillation cocktail for at least 5 h to allow equal dis-
tribution of radioactivity and then subjected to liquid
scintillation counting. The drug concentrations that could
be assayed ranged from 0.1 to 100 nM.
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Data handling and statistical analyses
For all convulsion experiments, data were expressed as the
percent of rats that convulsed in each treatment group of six
to eight rats. For convulsion threshold experiments, the
threshold dose of SNC80 was calculated by multiplying the
infusion rate by the time necessary to produce convulsive
activity. In the forced swim test experiments, the total
counts for each behavior during the 15-min swim were
averaged within each treatment group. Statistical tests were
performed using one-way ANOVA with Dunnett’s post
hoc analysis (Graphpad Prism software). p<0.05 was ac-
cepted as statistical significance. For [3H]NTI-binding
studies, standard curves and extrapolated unknown values





(SNC80) was dissolved in 8% of 1N HCl. Naltrindole was
dissolved in sterile water. All drugs were administered in
a volume of 1 ml kg−1. For binding studies, a stock
solution of 10 mM SNC80 was made as described above
and diluted in 0.1% BSA solution for standard curve
determinations.
Results
SNC80 administration by fast (20 s) i.v. infusion
Fast 20-s infusions of intravenous administration of
SNC80 (IV SNC80) produced convulsions in 66% of rats
at 1.0 mg kg−1 and 100% of rats at 3.2 and 10 mg kg−1
(Fig. 1a). Doses higher than 10 mg kg−1 IV SNC80 were
lethal. Convulsions produced by 1.0 and 3.2 mg kg−1 IV
SNC80 occurred during the infusion or immediately after
the infusion and appeared similar in form to convulsions
induced by subcutaneous administration of SNC80, as
determined by behavioral observation alone. The convul-
sions manifested as clonic contractions of the musculature
of the face, head, and forepaws, lasting 15–40 s, followed
by a period of catalepsy lasting 2–4 min. However,
convulsions produced by fast 20-s infusion of 10 mg kg−1
IV SNC80 were more severe as demonstrated by longer
Fig. 1 The effects of fast 20-s infusion of IV SNC80 on convulsive
(a) and antidepressant-like effects in the forced swim test (b) in
Sprague–Dawley rats (N=6 per dose). Drug was injected 30 min
prior to the forced swim test. The bars and vertical lines above each
bar represent the mean and standard error of the mean (SEM) for
immobility (open bars), swimming counts (single-hatched bars),
and climbing counts (double-hatched bars). * indicates p<0.05, and
** indicates p<0.01, as compared to vehicle as determined by
Dunnett’s post hoc test
Fig. 2 The effects of vehicle,
0.1, 1.0, or 10 mg kg−1 naltrin-
dole (NTI) administered (s.c.)
30 min prior to vehicle or
various doses of IV SNC80 on
convulsive (a) and antidepres-
sant-like effects in the forced
swim test (b) in Sprague–
Dawley rats (N=6 per condi-
tion). Antidepressant-like




durations (30–60 s), contractions of the whole body, and
myoclonic twitches observed throughout the catalepsy
period.
In the forced swim test, fast 20-s infusions of IV
SNC80 significantly decreased immobility [F(5,28)=15.49,
p<0.0001] and increased swimming and climbing be-
haviors [F(5,28)=5.70, p=0.0015 and F(5,28)=4.27,
p=0.0068, respectively] (Fig. 1b). Doses of 3.2 (p<0.01)
and 10 mg kg−1 (p<0.01) produced significant decreases in
immobility. Significant increases were observed in swim-
ming, with doses of 3.2 (p<0.05) and 10 mg kg−1 (p<0.01),
and in climbing, with a dose of 10 mg kg−1 (p<0.01).
As shown in Fig. 2a and b, the convulsive and anti-
depressant-like effects produced by fast 20-s infusion of
3.2 mg kg−1 IV SNC80were blocked by 1.0 and 10mg kg−1
NTI, but not by 0.1 mg kg−1 of NTI, similar to that
previously observed with subcutaneous administration of
SNC80 (SC SNC80) (Broom et al. 2002a). NTI alone did
not produce convulsions and did not have an effect in the
forced swim test. The effects of 10 mg kg−1 IV SNC80,
administered by 20-s infusion, were not antagonized by any
dose of NTI tested.
The dose–effect curve for convulsions produced by
fast 20-s IV SNC80 was shifted approximately 30-fold to
the left of the SC SNC80 dose–effect curve (Fig. 3a). In
the forced swim test, similar doses of IV SNC80 and
SC SNC80 produced significant decreases in immobility
(Fig. 3b); however, fast 20-s infusions with 3.2 and 10 mg
kg−1 SNC80 produced a larger decrease in immobility from
control values as compared with SC SNC80.
SNC80 administration by slow i.v. infusions
The effects of slow IV SNC80 infusions (20 or 60 min)
on convulsions and immobility, as compared to 20-s fast
infusions, are shown in Fig. 4a and b. With a single
SNC80 dose infused over 20 min (Fig. 4a), 33 and 83%
of rats convulsed with 3.2 and 10 mg kg−1 IV SNC80,
respectively. With a 60-min infusion of a single SNC80
dose (Fig. 4a), only one (17%) out of six rats convulsed
with 10 mg kg−1 IV SNC80. All convulsions produced
by slow infusions appeared similar to typical delta-opi-
oid receptor-mediated convulsions (Broom et al. 2002a;
Jutkiewicz et al. 2004). The dose–effect curve for con-
vulsions was shifted to the right by increasing the dura-
tion of i.v. infusion. Downward shifts of the dose–effect
curve were not thoroughly evaluated by testing slow
infusions of higher doses. Although the rate of drug in-
fusion affected the number of rats convulsing, changing
the rate of i.v. infusion did not alter the decrease in
immobility observed with 3.2 and 10 mg kg−1 IV SNC80
in the forced swim test (Fig. 4b).
Fig. 3 Comparison of the
convulsive (a) and antidepres-
sant-like effects (b) of SNC80
measured following s.c. admin-
istration or fast 20-s IV SNC80
infusion (N=6 per dose). Drug
was injected 60 min prior to the
forced swim test for s.c. admin-
istration or 30 min prior to the
forced swim test for IV SNC80.
Antidepressant-like effects are
expressed as mean immobility
counts only
Fig. 4 The effects of IV SNC80
by fast 20-s, slow 20-min, or
slow 60-min infusions on con-
vulsions (a) and antidepressant-
like effects in the forced swim
test (b). Vehicle or a single dose
of IV SNC80 was infused over
the duration listed above, and
rats were exposed to the swim
session 30 min after the
termination of the infusion.
Antidepressant-like effects are
expressed as mean immobility
counts only
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As shown in Fig. 5a and b, 10 mg kg−1 NTI was
administered prior to different infusion rates of 10 mg kg−1
IV SNC80. As described earlier, NTI did not antagonize
the convulsions or antidepressant-like effects produced by
fast 20-s infusions of 10 mg kg−1 IV SNC80. However,
10 mg kg−1 NTI completely attenuated the convulsions and
antidepressant-like effects observed with 20- and 60-min
slow infusions of 10 mg kg−1 IV SNC80 [F(2,17)=36.73,
p<0.001 and F(2,17)=17.62, p=0.0001, respectively].
Convulsions, antidepressant-like effects,
and brain concentrations of SNC80
With the slow infusions of IV SNC80, convulsions oc-
curred during the infusion. The SNC80 dose that had
been infused at the time of the convulsion was calculated
by multiplying the infusion rate by the time that the
convulsion occurred, shown in Table 1. The convulsions
observed with a 20-min slow infusion of 3.2 and 10 mg
kg−1 IV SNC80 occurred when 2.6 (±0.6) and 3.07
(±0.14) mg kg−1, respectively, were infused. With a 60-min
infusion of 10 mg kg−1 IV SNC80, one out of six rats
convulsed at a dose of 2.28 mg kg−1 IV SNC80. Over-
all, rats either convulsed with an average dose of 2.85±
0.18 mg kg−1 during slow infusions of IV SNC80, in-
dependent of dose or infusion duration, or they did not
convulse at all during the 20- or 60-min infusions.
The average brain concentrations of SNC80 equiva-
lents, presumably comprising of the parent compound
and/or its delta-opioid receptor-selective metabolite, (+)
BW373U86 (Schetz et al. 1996), were measured 30 min
after administration of various doses of IV SNC80 at
different infusion durations (or at the time of swim).
Table 2 shows these calculated drug levels in brain
homogenates from treated rats. Fast infusions of IV
SNC80 over 20-s and 20-min slow infusions produced
dose-dependent increases in drug concentrations and
similar levels of delta-opioid ligands in the brain. Fol-
lowing a 60-min infusion of 1.0 mg kg−1 IV SNC80,
brain levels of drug were low and could not be ac-
curately measured; however, with 3.2 and 10 mg kg−1,
drug levels were lower than that observed with other
infusion durations.
Table 1 Average dose of IV SNC80 that produced convulsions in











20 3.2 2/6 2.60 (0.6)
10 5/6 3.07 (0.14)
60 10 1/6 2.28
Table 2 Brain equivalents of the delta-opioid agonist SNC80 or its
delta-opioid metabolite measured 30 min following the termination








20 s 1 1.86 (0.71)
3.2 12.1 (6.46)
10 >100
20 min 1 0.87 (0.36)
3.2 11.73 (0.87)
10 >100
60 min 1 <0.1
3.2 4.76 (1.56)
10 11.23 (2.36)
Fig. 5 The effects of 10 mg kg−1 NTI administered (s.c.) 30 min
prior to IV SNC80 by fast 20-s, slow 20-min, or slow 60-min infu-
sions on the convulsive (a) and antidepressant-like effects in the
forced swim test (b) in Sprague–Dawley rats (N=6 per condition).
The bars and vertical lines above each bar represent the mean and
standard error of the mean (SEM) for SNC80 alone (open bars),
10 mg kg−1 SNC80 alone (single-hatched bars), or 10 mg kg−1
NTI administered prior to 10 mg kg−1 SNC80 (double-hatched
bars). ** indicates p<0.01 as compared to Ctrl determined by one-
way ANOVA with Dunnett’s post hoc test
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Convulsive threshold and tolerance development
To investigate potential tolerance development follow-
ing SNC80 exposure, rats were injected with vehicle or
various doses of SC SNC80 1 h prior to SNC80 in-
fusions of 0.5 mg kg−1 min−1 for convulsive threshold
determinations (Table 3). As the SNC80 pretreatment
dose increased, the number of rats convulsing during
the SNC80 infusion decreased, the threshold dose for
convulsions increased, and the maximum overall dose
infused increased (maximum dose infused was limited
to 30 mg kg−1). With higher pretreatment doses, more
rats were infused with 30 mg kg−1 SNC80 and did not
convulse; thus, these rats received a dose tenfold higher
than the average convulsive threshold determined in vehi-
cle-pretreated rats.
Discussion
Intravenous administration of SNC80 produced convul-
sions and antidepressant-like effects in the forced swim
test in male Sprague–Dawley rats. In general, IV SNC80
and SC SNC80 produced similar behavioral effects; how-
ever, IV SNC80 was approximately 30-fold more potent in
producing convulsions than SC SNC80. In the forced swim
test, similar doses of IV SNC80 and SC SNC80 produced
antidepressant-like effects, although IV SNC80 produced a
larger magnitude of effect as compared to SC SNC80 at
similar doses. At high doses, fast IV SNC80 produced
nondelta-opioid receptor-mediated convulsions and anti-
depressant-like effects, as these effects were not blocked
by NTI. Importantly, slowing the rate of IV SNC80
infusions decreased the number of rats convulsing without
altering the antidepressant-like effects of SNC80.
SNC80-induced convulsions
Slow i.v. infusions of SNC80 might have decreased con-
vulsive episodes for multiple reasons. One obvious ex-
planation was that slow infusions of SNC80 failed to reach
the necessary levels of drug in the brain. As demonstrated
in Table 1, the convulsive event appeared closely related to
the level of SNC80 at the time of convulsion, such that
convulsions occurred after an average dose of 2.85 mg kg−1
SNC80. However, not all rats convulsed after receiving
this dose, especially with slow infusion rates. Additionally,
fast infusions of the lowest dose (1.0 mg kg−1) produced
convulsions. These data suggested that a certain dose of
SNC80 might be necessary for convulsion but was not the
only factor controlling this behavioral outcome.
Slower rates of SNC80 administration might decrease
convulsions by leading to lower drug levels in the vicinity
of the delta-opioid receptor and slower rates of receptor
activation at any given moment as compared with fast i.v.
infusions. It was previously reported that the temporal
pattern of synaptic activation was important in producing
cocaine sensitization (Samaha et al. 2002) and long-term
potentiation (Larson et al. 1986; Tsukada et al. 1994;
Greenstein et al. 1998). This theory suggested that the
timing of receptor activation might be a critical component
of the intracellular processes producing convulsions. For
example, activation of delta-opioid receptors, depending
on the number of receptors occupied at a single moment,
might alter the pattern of neuronal firing (Law 2004) and
thus decrease the manifestation of convulsions. Therefore,
fast infusions of 1.0 mg kg−1 SNC80 might produce con-
vulsions by rapid receptor activation, thus attaining the
pattern of neuronal activity required for a convulsion.
Likewise, 60-min slow infusions of IV SNC80 might not
activate enough receptors simultaneously to produce
convulsions. Therefore, slow infusions of IV SNC80
potentially minimized convulsions by reducing the rate of
receptor activation.
An alternative or added explanation for decreased con-
vulsive events with slow infusions was that the rats became
tolerant to the convulsant effects of SNC80 following
prolonged drug exposure. With long infusion durations,
delta-opioid receptors can become desensitized and, per-
haps, down-regulated. This hypothesis would suggest that
there is a small receptor reserve for delta-opioid agonist-
induced convulsions (Broom et al. 2002c). As demonstrat-
ed by the convulsive threshold data in Table 3, previous
SNC80 exposure decreased the number of rats convulsing,
increased the total amount of drug infused, and increased
the threshold dose required for convulsions. These data
suggested that exposure to SNC80 produced rapid toler-
ance to the convulsive effects of SNC80.
To summarize, SNC80-induced convulsions might be
influenced by some level or pattern of delta-opioid receptor
activation and the number of functional delta-opioid re-
ceptors. Therefore, low levels of simultaneous receptor
activation and/or tolerance development might prevent this
hypothetical pattern of receptor activation (or threshold
dose) required for convulsions. Overall, the results sug-
gested that brain concentrations of drug, the rate of receptor
activation, and tolerance development might be contribut-
ing factors in the elimination of the SNC80-induced con-
vulsion following slow rates of drug administration.
Table 3 The effects of a SNC80 pretreatment (s.c.) 1 h prior to dose












Vehicle 6/6 3.11 (0.19) 3.11 (0.19)
0.1 5/6 7.80 (4.44) 3.36 (0.16)
0.32 4/6 12.47 (5.55) 3.70 (0.81)
1.0 4/6 13.20 (5.32) 4.80 (0.47)
3.2 2/6 21.45 (5.41) 4.36 (0.43)
10 0/6 30 N/A
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SNC80-induced antidepressant-like effect
Despite the nearly eliminated convulsion, the antidepres-
sant-like effects of slow infusions of IV SNC80 did not
change as compared to fast i.v. infusions, suggesting that
the factors contributing to convulsive effects are not as
relevant to antidepressant-like effects. With i.v. doses of 3.2
and 10 mg kg−1 SNC80, the antidepressant-like effects did
not change in magnitude or absolute effect with the
different infusion durations tested. Based on brain concen-
tration studies measured at the time of the swim test
(Table 2), the antidepressant-like effects appeared to be
independent of whole-brain concentration of delta-opioid
ligands. For example, following a 60-min infusion, there
was less drug in the brain at any specific dose as compared
with 20-s and 20-min infusions; however, the magnitude
of the antidepressant-like effect did not change with
different infusion durations. These data suggested that
whole-brain concentrations at the time of the swim were
not a critical factor in the antidepressant actions of SNC80
once certain levels were reached. However, SNC80 levels
in specific brain regions might be a determining factor for
antidepressant actions and should be considered in future
studies. Additionally, tolerance development and patterns
of receptor activation or neuronal firing did not alter
antidepressant effects, as was observed with convulsions.
These data suggested that there was a large receptor
reserve for the SNC80-induced antidepressant-like effects,
and that mechanisms downstream of the delta-opioid
receptor might have a more significant role in the
antidepressant actions of delta-opioid agonists.
Overall, these findings suggested that different mecha-
nisms of action generate the nonpeptidic delta-opioid ago-
nist-induced convulsions and antidepressant-like effects, as
these behaviors were differentially influenced by whole-
brain drug concentration, drug administration rate, and
tolerance development. This study supported previous find-
ings demonstrating that delta-opioid agonists display anti-
depressant properties and may have therapeutic potential
for treating depression. However, SNC80 also produced
delta-opioid receptor convulsions, severely limiting its po-
tential clinical utility. Slow infusions of delta-opioid recep-
tor agonists nearly eliminated convulsions without altering
the antidepressant properties of these compounds. These
data highlighted the independent natures of the convulsive
and antidepressant-like effects and suggested that these two
behavioral outcomes can be separated. Based on these
findings, slow-release formulations of delta-opioid agonists
would be interesting to study and might provide therapeutic
utility without negative side effects.
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